{"id":"solifenacin-with-vaginal-estrogen-cream","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Dry mouth"},{"rate":"5-15%","effect":"Constipation"},{"rate":"2-5%","effect":"Blurred vision"},{"rate":"1-3%","effect":"Urinary retention"},{"rate":"1-5%","effect":"Vaginal irritation or spotting (from estrogen cream)"}]},"_chembl":{"chemblId":"CHEMBL1200803","moleculeType":"Small molecule","molecularWeight":"480.56"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Solifenacin is an anticholinergic agent that inhibits M3 muscarinic receptors on bladder smooth muscle, decreasing involuntary contractions and urgency. Vaginal estrogen cream provides localized estrogen replacement to restore vaginal epithelial health, improve lubrication, and reduce urogenital atrophy symptoms. Together, they address both the neurogenic and hormonal components of overactive bladder and urogenital dysfunction in postmenopausal women.","oneSentence":"Solifenacin blocks muscarinic receptors to reduce overactive bladder contractions, while vaginal estrogen cream restores local estrogen levels to improve vaginal atrophy and urogenital symptoms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:08:48.272Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Overactive bladder with urge incontinence in postmenopausal women"},{"name":"Urogenital atrophy and vaginal dryness associated with menopause"}]},"trialDetails":[{"nctId":"NCT06197295","phase":"PHASE4","title":"Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity","status":"RECRUITING","sponsor":"Mackay Memorial Hospital","startDate":"2022-06-16","conditions":"Urinary Bladder, Overactive, Effect of Drug","enrollment":200},{"nctId":"NCT06479720","phase":"PHASE4","title":"Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder","status":"RECRUITING","sponsor":"Mackay Memorial Hospital","startDate":"2022-06-16","conditions":"Effect of Drug, Urinary Bladder, Overactive","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vesicare and Premarin","Premarin"],"phase":"marketed","status":"active","brandName":"Solifenacin with vaginal estrogen cream","genericName":"Solifenacin with vaginal estrogen cream","companyName":"Mackay Memorial Hospital","companyId":"mackay-memorial-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Solifenacin blocks muscarinic receptors to reduce overactive bladder contractions, while vaginal estrogen cream restores local estrogen levels to improve vaginal atrophy and urogenital symptoms. Used for Overactive bladder with urge incontinence in postmenopausal women, Urogenital atrophy and vaginal dryness associated with menopause.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}